|
1
|
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman
M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C,
et al: Heart disease and stroke statistics-2017 update: A report
from the American heart association. Circulation. 135:e146–e603.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Welsh P, Grassia G, Botha S, Sattar N and
Maffia P: Targeting inflammation to reduce cardiovascular disease
risk: A realistic clinical prospect? Br J Pharmacol. 174:3898–3913.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ridker PM, Everett BM, Thuren T, MacFadyen
JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker
SD, et al: Antiinflammatory therapy with canakinumab for
atherosclerotic disease. N Engl J Med. 377:1119–1131. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ridker PM, Hennekens CH, Buring JE and
Rifai N: C-reactive protein and other markers of inflammation in
the prediction of cardiovascular disease in women. N Engl J Med.
342:836–843. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Duewell P, Kono H, Rayner KJ, Sirois CM,
Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr
M, et al: NLRP3 inflammasomes are required for atherogenesis and
activated by cholesterol crystals. Nature. 464:1357–1361. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kingsbury SR, Conaghan PG and McDermott
MF: The role of the NLRP3 inflammasome in gout. J Inflamm Res.
4:39–49. 2011.PubMed/NCBI
|
|
7
|
Toldo S, Mezzaroma E, Mauro AG, Salloum F,
Van Tassell BW and Abbate A: The inflammasome in myocardial injury
and cardiac remodeling. Antioxid Redox Signal. 22:1146–1161. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Satoh M, Tabuchi T, Itoh T and Nakamura M:
NLRP3 inflammasome activation in coronary artery disease: Results
from prospective and randomized study of treatment with
atorvastatin or rosuvastatin. Clin Sci (Lond). 126:233–241. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schroder K, Zhou R and Tschopp J: The
NLRP3 inflammasome: A sensor for metabolic danger? Science.
327:296–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rajamäki K, Lappalainen J, Oörni K,
Välimäki E, Matikainen S, Kovanen PT and Eklund KK: Cholesterol
crystals activate the NLRP3 inflammasome in human macrophages: A
novel link between cholesterol metabolism and inflammation. PLoS
One. 5:e117652010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
No authors listed, . Randomised trial of
cholesterol lowering in 4444 patients with coronary heart disease:
The scandinavian simvastatin survival study (4S). Lancet.
344:1383–1389. 1994.PubMed/NCBI
|
|
12
|
Ridker PM, Danielson E, Fonseca FA, Genest
J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ,
MacFadyen JG, et al: Rosuvastatin to prevent vascular events in men
and women with elevated C-reactive protein. N Engl J Med.
359:2195–2207. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz
P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S and Stern
T; Myocardial Ischemia Reduction with Aggressive Cholesterol
Lowering (MIRACL) Study Investigators, : Effects of atorvastatin on
early recurrent ischemic events in acute coronary syndromes: The
MIRACL study: A randomized controlled trial. JAMA. 285:1711–1718.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zacà V, Rastogi S, Imai M, Wang M, Sharov
VG, Jiang A, Goldstein S and Sabbah HN: Chronic monotherapy with
rosuvastatin prevents progressive left ventricular dysfunction and
remodeling in dogs with heart failure. J Am Coll Cardiol.
50:551–557. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ren Y, Zhu H, Fan Z, Gao Y and Tian N:
Comparison of the effect of rosuvastatin versus
rosuvastatin/ezetimibe on markers of inflammation in patients with
acute myocardial infarction. Exp Ther Med. 14:4942–4950.
2017.PubMed/NCBI
|
|
16
|
Karlson BW, Nicholls SJ, Lundman P, Barter
PJ and Palmer MK: Modeling statin-induced reductions of
cardiovascular events in primary prevention: A VOYAGER
meta-Analysis. Cardiology. 140:30–34. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fihn SD, Gardin JM, Abrams J, Berra K,
Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC,
Hinderliter AL, et al: 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS
guideline for the diagnosis and management of patients with stable
ischemic heart disease: Executive summary: A report of the American
college of cardiology foundation/American heart association task
force on practice guidelines, and the American College of
physicians, American association for thoracic surgery, preventive
cardiovascular nurses association, society for cardiovascular
angiography and interventions, and society of thoracic surgeons.
Circulation. 126:3097–3137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Thygesen K, Alpert JS, Jaffe AS, Simoons
ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for
the Universal Definition of Myocardial Infarction, ; Katus HA,
Lindahl B, Morrow DA, et al: Third universal definition of
myocardial infarction. Circulation. 126:2020–2035. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Giampietro C, Lionetti MC, Costantini G,
Mutti F, Zapperi S and La Porta CA: Cholesterol impairment
contributes to neuroserpin aggregation. Sci Rep. 7:436692017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Marchant DJ, Boyd JH, Lin DC, Granville
DJ, Garmaroudi FS and McManus BM: Inflammation in myocardial
diseases. Circ Res. 110:126–144. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weber C and Soehnlein O: ApoE controls the
interface linking lipids and inflammation in atherosclerosis. J
Clin Invest. 121:3825–3827. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Husain K, Hernandez W, Ansari RA and
Ferder L: Inflammation, oxidative stress and renin angiotensin
system in atherosclerosis. World J Biol Chem. 6:209–217. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo H, Callaway JB and Ting JP:
Inflammasomes: Mechanism of action, role in disease, and
therapeutics. Nat Med. 21:677–687. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Martinon F, Burns K and Tschopp J: The
inflammasome: A molecular platform triggering activation of
inflammatory caspases and processing of proIL-beta. Mol Cell.
10:417–426. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lamkanfi M and Dixit VM: Mechanisms and
functions of inflammasomes. Cell. 157:1013–1022. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Muñoz-Planillo R, Kuffa P, Martinez-Colón
G, Smith BL, Rajendiran TM and Núñez G: K+ efflux is the
common trigger of NLRP3 inflammasome activation by bacterial toxins
and particulate matter. Immunity. 38:1142–1153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alfonso-Loeches S, Ureña-Peralta JR,
Morillo-Bargues MJ, Oliver-De La Cruz J and Guerri C: Role of
mitochondria ROS generation in ethanol-induced NLRP3 inflammasome
activation and cell death in astroglial cells. Front Cell Neurosci.
8:2162014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hornung V, Bauernfeind F, Halle A, Samstad
EO, Kono H, Rock KL, Fitzgerald KA and Latz E: Silica crystals and
aluminum salts activate the NALP3 inflammasome through phagosomal
destabilization. Nat Immunol. 9:847–856. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Toldo S and Abbate A: The NLRP3
inflammasome in acute myocardial infarction. Nat Rev Cardiol.
15:203–214. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Galea J, Armstrong J, Gadsdon P, Holden H,
Francis SE and Holt CM: Interleukin-1 beta in coronary arteries of
patients with ischemic heart disease. Arterioscler Thromb Vasc
Biol. 16:1000–1006. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Blankenberg S, Tiret L, Bickel C, Peetz D,
Cambien F, Meyer J and Rupprecht HJ; AtheroGene Investigators, :
Interleukin-18 is a strong predictor of cardiovascular death in
stable and unstable angina. Circulation. 106:24–30. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takahashi M: NLRP3 inflammasome as a novel
player in myocardial infarction. Int Heart J. 55:101–105. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kawaguchi M, Takahashi M, Hata T, Kashima
Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J,
et al: Inflammasome activation of cardiac fibroblasts is essential
for myocardial ischemia/reperfusion injury. Circulation.
123:594–604. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Toldo S, Marchetti C, Mauro AG, Chojnacki
J, Mezzaroma E, Carbone S, Zhang S, Van Tassell B, Salloum FN and
Abbate A: Inhibition of the NLRP3 inflammasome limits the
inflammatory injury following myocardial ischemia-reperfusion in
the mouse. Int J Cardiol. 209:215–220. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bullón P, Cano-García FJ, Alcocer-Gómez E,
Varela-López A, Roman-Malo L, Ruiz-Salmerón RJ, Quiles JL,
Navarro-Pando JM, Battino M, Ruiz-Cabello J, et al: Could
NLRP3-inflammasome be a cardiovascular risk biomarker in acute
myocardial infarction patients? Antioxid Redox Signal. 27:269–275.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Verma S, Buchanan MR and Anderson TJ:
Endothelial function testing as a biomarker of vascular disease.
Circulation. 108:2054–2059. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Szmitko PE, Wang CH, Weisel RD, de Almeida
JR, Anderson TJ and Verma S: New markers of inflammation and
endothelial cell activation: Part I. Circulation. 108:1917–1923.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yip HK, Wu CJ, Hang CL, Chang HW, Yang CH,
Hsieh YK, Fang CY, Fu M, Yeh KH and Chen MC: Levels and values of
inflammatory markers in patients with angina pectoris. Int Heart J.
46:571–581. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fiechter M, Ghadri JR, Jaguszewski M,
Siddique A, Vogt S, Haller RB, Halioua R, Handzic A, Kaufmann PA,
Corti R, et al: Impact of inflammation on adverse cardiovascular
events in patients with acute coronary syndromes. J Cardiovasc Med
(Hagerstown). 14:807–814. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ference BA, Ginsberg HN, Graham I, Ray KK,
Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H,
et al: Low-density lipoproteins cause atherosclerotic
cardiovascular disease. 1. Evidence from genetic, epidemiologic,
and clinical studies. A consensus statement from the European
atherosclerosis society consensus panel. Eur Heart J. 38:2459–2472.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tousoulis D, Andreou I, Tsiatas M, Miliou
A, Tentolouris C, Siasos G, Papageorgiou N, Papadimitriou CA,
Dimopoulos MA and Stefanadis C: Effects of rosuvastatin and
allopurinol on circulating endothelial progenitor cells in patients
with congestive heart failure: The impact of inflammatory process
and oxidative stress. Atherosclerosis. 214:151–157. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Altaf A, Qu P, Zhao Y, Wang H, Lou D and
Niu N: NLRP3 inflammasome in peripheral blood monocytes of acute
coronary syndrome patients and its relationship with statins. Coron
Artery Dis. 26:409–421. 2015. View Article : Google Scholar : PubMed/NCBI
|
